NCT06395519 - A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced or Metastatic Solid TumorsBreast CancerOvarian CancerProstate CancerEpithelial Ovarian CancerBRCA2 MutationER+ Breast CancerCastrate Resistant Prostate CancerBRCA1 MutationBRCA MutationEndometrial CancerColorectal CancerGastric Cancer

Interventions

DRUG

ETX-19477

Oral medication taken daily

Trial Locations (12)

10016

RECRUITING

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

19107

RECRUITING

Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

32224

RECRUITING

Mayo Clinic, Jacksonville

55905

RECRUITING

Mayo Clinic, Rochester

77030

RECRUITING

MD Anderson Cancer Center, Houston

84112

RECRUITING

START Center for Cancer Care - Mountain Region, Salt Lake City

85054

RECRUITING

Mayo Clinic, Phoenix

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

06510

RECRUITING

Yale University, Yale Cancer Center, New Haven

02114

RECRUITING

Massachusetts General Hospital, Boston